Last reviewed · How we verify
NCT06873178: PCLM:CSSG
The Significance and Indications of Surgery for Synchronous Liver Metastatic Pancreatic Cancer
trial in Pancreatic Cancer in 50 participants. Participants enrolled and being followed up; not accepting new ones.
30 April 2026
Quick facts
| Lead sponsor | China-Japan Friendship Hospital |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 23 August 2024 |
| Primary completion | 30 April 2026 |
| Estimated completion | 30 June 2026 |
| Sites | 1 location across China |
Conditions studied
- Pancreatic Cancer — all drugs for Pancreatic Cancer →
- Liver Metastases — all drugs for Liver Metastases →
- Surgery — all drugs for Surgery →
- Adjuvant Therapy — all drugs for Adjuvant Therapy →
Sponsor
China-Japan Friendship Hospital
Who can join
Adults 18 to 75, any sex, with Pancreatic Cancer or Liver Metastases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To explore the clinical characteristics of pancreatic cancer patients with liver metastases who can benefit from surgery, and to develop evaluation criteria for surgical indications, so as to provide basis for comprehensive treatment strategies for advanced pancreatic cancer patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06873178
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pancreatic Cancer
Currently open trials in the same condition.
- NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
- NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
- NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting
Other China-Japan Friendship Hospital trials
Trials by the same sponsor.
- NCT07482995 — Effects of Baduanjin Exercise on Improving Health in Sedentary Young and Middle-Aged Adults · NA · not yet recruiting
- NCT07406932 — A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial L · NA · not yet recruiting
- NCT07509775 — Integrated Traditional Chinese and Western Medicine for Ankylosing Spondylitis (AS): A Cohort Study Protocol Focusing on · recruiting
- NCT07339956 — Yiwei Jiaohuang Ointment for Gastrointestinal Bleeding Associated With Oral Antithrombotic Agents · EARLY_PHASE1 · not yet recruiting
- NCT07280429 — ICIAM Rehabilitation Program Study: A Randomized Controlled Trial · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06873178 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by China-Japan Friendship Hospital
- Last refreshed: 16 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06873178.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing